Download MendeleyIdentification of the Clinical Candidate PF-07284890 ( ARRY-461 ), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer.
Ren, L., Moreno, D., Baer, B.R., Barbour, P., Bettendorf, T., Bouhana, K., Brown, K., Brown, S.A., Fell, J.B., Hartley, D.P., Hicken, E.J., Laird, E.R., Lee, P., McCown, J., Otten, J.N., Prigaro, B., Wallace, R., Kahn, D.(2024) J Med Chem 67: 13019-13032
- PubMed: 39077892
- DOI: https://doi.org/10.1021/acs.jmedchem.4c00998
- Primary Citation of Related Structures:
9BFB - PubMed Abstract:
Mutant BRAF V600E is one of the most common oncogenic drivers in metastatic melanoma. While first generation BRAF V600E inhibitors are capable of controlling tumors systemically, they are unable to adequately treat tumors that have metastasized to the brain due to insufficient penetration across the blood-brain barrier (BBB). Through a combination of structure-based drug design (SBDD) and the optimization of physiochemical properties to enhance BBB penetration, we herein report the discovery of the brain-penetrant BRAF V600E inhibitor PF-07284890 ( ARRY-461 ) . In mice studies, ARRY-461 proved to be highly brain-penetrant and was able to drive regressions of A375 BRAF V600E tumors implanted both subcutaneously and intracranially. Based on compelling preclinical safety and efficacy studies, ARRY-461 was progressed into a Phase 1 A/B clinical trial (NCT04543188).
Organizational Affiliation:
Enliven Therapeutics, Boulder, Colorado 80301, United States.
